Colorectal Cancer

General Cancer

Consistent benefits and safety were seen with TAS-102 (trifluridine/tipiracil; Lonsurf) in a real-world treatment setting for patients with refractory metastatic colorectal cancer, according to preliminary data from the phase IIIb open-label PRECONNECT trial. 

A strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day in patients with refractory metastatic colorectal cancer, according to results from the regorafenib dose optimization study presented at the 2018 World Congress on GI.

According to findings from the IMblaze370 study, atezolizumab alone or in combination with cobimetinib did not demonstrate superior overall survival when compared with regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer. Findings from the study were presented at the 2018 World Congress on Gastrointestinal Cancer.

Treatment with&nbsp;trifluridine/tipiracil combined with bevacizumab improved&nbsp;progression-free survival over capecitabine plus bevacizumab in patients with&nbsp;metastatic colorectal cancer who are not eligible for chemotherapy or surgical resection,&nbsp;according to findings presented at the 20th World Conference of Gastrointestinal Cancer.&nbsp;<br /> &nbsp;

Bert H. O&rsquo;Neil, MD, recently shared his considerations for treatment when treating patients with gastrointestinal cancers. O&rsquo;Neil reviewed how he would treat patients with colon cancer and patients with hepatocellular carcinoma based on case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.<br /> &nbsp;

Things are looking up in the world of adjuvant therapy for patients with gastrointestinal cancers, according to Diane Reidy-Lagunes, MD.&nbsp;During her presentation, Reidy-Lagunes outlined the current state-of-the-art in GI cancer care, with findings from pivotal studies in gastric, pancreatic, biliary, and colorectal cancers.

The Hutchinson Institute for Cancer Outcomes Research released the first Community Care Cancer in Washington State: Quality and Cost Report to provide transparency for patients and health providers, establishing a more value-based care model.

In patients with&nbsp;peritoneal carcinomatosis undergoing surgery, the addition of heated chemotherapy to the abdomen during surgery did not provide a survival benefit, data&nbsp;from a phase III study presented at the 2018 ASCO Annual Meeting, in Chicago, Illinois, showed.

According to the results of a study presented during the 2018 ASCO Annual Meeting, microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome.&nbsp;

Prices for treatment of metastatic colorectal cancer were more than twice as high for US patients than for their Canadian counterparts, according to a study of costs of treatment in Western Washington (WW) and the province of British Columbia (BC) in Canada.

In the first report of the full cohort of 119 patients in the CheckMate-142 study, positive results were demonstrated with nivolumab alone or in combination with ipilimumab in patients with previously treated microsatellite instability-high or DNA mismatch repair-deficient metastatic colorectal cancer.

According to topline findings from the phase III IMblaze370 study, treatment with the combination of the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in patients with locally advanced or metastatic colorectal cancer&nbsp; who were previously treated.

The beginning of 2018 has brought many exciting developments in the treatment landscape of metastatic colorectal cancer, explains Shubham Pant, MD.

While not all patients with gastrointestinal cancers will respond to immunotherapy, those who do&nbsp;are likely to have long-lasting responses, explained John L. Marshall, MD.